Project Grant R43AI134225

This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $3,309,999.00 to Moonlight Therapeutics, Inc., a minority-owned company in Marietta, Georgia, to develop a peanut allergy treatment for adults using microneedle technology. The funding supports various stages of research, including pre-clinical development, manufacturing scale-up, and clinical trials to evaluate the safety and tolerability of this...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $806,466 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The 5-year grant, with a start date of August 1, 2025, aims to define the IgG antibody signatures associated with successful peanut oral immunotherapy (OIT) treatment outcomes. The research will characterize the peanut-specific IgG...

The National Institute of Allergy and Infectious Diseases (NIAID), as part of the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $300,000 Project Grant to Cellergy Pharma Inc. The grant, effective February 1, 2025 through January 31, 2027, supports the development of a bispecific antibody drug targeting IgE-producing B cells to treat severe allergic diseases. The key products and services to be delivered under this Phase I grant include: Determining the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to determine whether acquired tick resistance (ATR) can be induced against the Amblyomma americanum tick. The goal is to develop an mRNA-based vaccine to prevent alpha-gal syndrome, an IgE-mediated allergy to red meat caused by A. americanum tick bites. The $251,250 award to Yale University will fund...

This $250,000 Project Grant was awarded on August 21, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to develop a prognostic signature of systemic immune dynamics for IgE/Th2-mediated food allergies, using a novel synthetic immunological niche technology. The goal is to distinguish the heterogeneity of allergic responses and monitor immune responses to...

Ingateygen LLC received a $1.2 million cooperative agreement award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an allergen-free peanut using genome editing technology. The award, issued on April 15, 2021, will support the project through September 30, 2023 in Elizabeth City, North Carolina. The NSF Technology, Innovation, and Partnerships program seeks to advance science, engineering, and technology solutions to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), with a CFDA number of 93.855, provides $314,347 in funding to Gateway Bio Inc. for the period from September 23, 2025 to August 31, 2026. The project aims to develop a new lipid nanoparticle (LNP) delivery system for mRNA payloads that uses a proprietary polyethylene glycol (PEG) alternative called POEGMA. This novel LNP is intended to address concerns around PEG-related allergies and reduced...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $307,091 Project Grant to Aleutian Therapeutics, Inc. under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The objective of this Phase I research is to develop immune evasive strategies for allogeneic (non-self) cell replacement therapies, specifically by ascertaining the minimal number of genetic edits required to enable human pluripotent stem cells to overcome xenogeneic...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $547,988 Project Grant to the University of Pittsburgh under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025. The funding supports the development and testing of a novel monkeypox vaccine based on a replication-inducible version of the ACAM2000 smallpox vaccine. The proposed vaccine aims to retain the immunogenicity of ACAM2000 while reducing adverse side effects, particularly for...

This $314,363 Project Grant was awarded on September 11, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research grant program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit company based in Austin, Texas. The grant supports the development of a microneedle-based mRNA flu vaccine for transcutaneous immunization. The goal is to create a stable, patient-friendly influenza vaccine delivered through the skin rather than by...